DESTINY-Breast09: Favorable PROs with T-DXd plus pertuzumab in first-line HER2-positive advanced and metastatic breast cancer

ESMO 2025

Breast Cancer

DESTINY-Breast09: T-DXd plus placebo shows superior efficacy over THP across subgroups in HER2-positive advanced or metastatic breast cancer

ESMO 2025

Breast Cancer

DESTINY-Breast11: Neoadjuvant T-DXd plus THP significantly improves pCR in high-risk HER2-positive early breast cancer

SABCS 2025

Breast Cancer

DESTINY-Breast11: T-DXd followed by THP shows manageable and more favorable safety profile versus ddAC–THP in patients with high-risk HER2-positive early breast cancer

Breast Cancer

Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial

J Clin Oncol

Yamashita T, Saji S, Takano T, Naito Y, Tsuneizumi M, Yoshimura A, Takahashi M, Tsurutani J, Iwatani T, Kitada M, Tada H, Mori N, Higuchi T, Iwasa T, Araki K, Koizumi K, Hasegawa H, Uchida Y, Morita S, Masuda N

doi: 10.1200/JCO-24-01888

CHICAGO 2025

Gastrointestinal Cancer

LBA4002: DESTINY-Gastric04: Improved OS with second-line T-Dxd versus ramucirumab plus paclitaxel in patients with HER2-positive metastatic GC/GEJA

ESMO 2025

Breast Cancer

LBA1: DESTINY-Breast05: T-DXd significantly improves IDFS and DFS versus T-DM1 in HER2-positive early breast cancer with residual invasive disease

CHICAGO 2025

Breast Cancer

LBA4: SERENA-6: Switching to camizestrant plus CDK4/6 inhibitor significantly delays progression in HR-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation in first line

SPECIAL REPORT

Breast Cancer

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

Breast Cancer

Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer

Eur J Cancer

Michel LL, Ziegler P, Kreis P, Hartkopf AD, Wallwiener M, Häberle L, John N, Kolberg HC, Hadji P, Tesch H, Ettl J, Lüftner D, Müller V, Belleville E, Wimberger P, Enzinger HM, Huebner H, Uhrig S, Hack CC, Krabisch P, Fasching PA, Wuerstlein R, Untch M, Ditsch N, Hein A, Janni W, Taran FA, Lux MP, Wallwiener D, Brucker SY, Fehm TN, Schneeweiss A, Goossens C, Engler T

doi: 10.1016/j.ejca.2025.115689

Related content

DESTINY-Breast09: T-DXd plus placebo shows superior efficacy over THP across subgroups in HER2-positive advanced or metastatic breast cancer

DESTINY-Breast11: Neoadjuvant T-DXd plus THP significantly improves pCR in high-risk HER2-positive early breast cancer

DESTINY-Breast11: T-DXd followed by THP shows manageable and more favorable safety profile versus ddAC–THP in patients with high-risk HER2-positive early breast cancer

Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial

LBA4002: DESTINY-Gastric04: Improved OS with second-line T-Dxd versus ramucirumab plus paclitaxel in patients with HER2-positive metastatic GC/GEJA

LBA1: DESTINY-Breast05: T-DXd significantly improves IDFS and DFS versus T-DM1 in HER2-positive early breast cancer with residual invasive disease

LBA4: SERENA-6: Switching to camizestrant plus CDK4/6 inhibitor significantly delays progression in HR-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation in first line

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer